Cargando…

Preclinical safety testing of an affinity-optimised MAGE-A10 T cell receptor for adoptive T cell therapy

Detalles Bibliográficos
Autores principales:	Gerry, Andrew, Sanderson, Joseph, Saini, Manoj, Tavano, Barbara, Docta, Roslin, Pumphrey, Nicholas, Maroto, Miguel, Border, Ellen, Bennett, Alan, Binder-Scholl, Gwendolyn, Holdich, Tom, Pandite, Lini, Amado, Rafael, Jakobsen, Bent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646050/ http://dx.doi.org/10.1186/2051-1426-3-S2-P14

Ejemplares similares

Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate
por: Border, Ellen C., et al.
Publicado: (2018)

Improved affinity AFP-specific T cell receptor for hepatocellular carcinoma
por: Gerry, Andrew B, et al.
Publicado: (2013)

Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy
por: Sanderson, Joseph P, et al.
Publicado: (2019)

Optimizing engineered TCR T cell therapy for synovial sarcoma
por: D'Angelo, Sandra, et al.
Publicado: (2015)

Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy
por: Simister, Philip C, et al.
Publicado: (2022)

Tuning T‐Cell Receptor Affinity to Optimize Clinical Risk‐Benefit When Targeting Alpha‐Fetoprotein–Positive Liver Cancer
por: Docta, Roslin Y., et al.
Publicado: (2019)

Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma
por: Davila, Eduardo, et al.
Publicado: (2015)

Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT
por: Rapoport, Aaron P, et al.
Publicado: (2013)

Process improvement and comparability analysis for engineered T cell manufacture
por: Melchiori, Luca, et al.
Publicado: (2014)

The Tumor Targeted Superantigen ABR-217620 Selectively Engages TRBV7-9 and Exploits TCR-pMHC Affinity Mimicry in Mediating T Cell Cytotoxicity
por: Hedlund, Gunnar, et al.
Publicado: (2013)

Pathogenicity of the MAGE family
por: Li, Sanyan, et al.
Publicado: (2021)

In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine
por: Junwei, Wang, et al.
Publicado: (2016)

Erratum to: In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine
por: Junwei, Wang, et al.
Publicado: (2017)

T cell receptor binding affinity governs the functional profile of cancer-specific CD8(+) T cells
por: Tan, M P, et al.
Publicado: (2015)

MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer
por: Suzuki, S, et al.
Publicado: (2008)

Human leucocyte antigen class I‐redirected anti‐tumour CD4(+) T cells require a higher T cell receptor binding affinity for optimal activity than CD8(+) T cells
por: Tan, M. P., et al.
Publicado: (2016)

Correction: Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy
Publicado: (2022)

Frequent MAGE Mutations in Human Melanoma
por: Caballero, Otavia L., et al.
Publicado: (2010)

Miltiwire proportional chambers MAGE spectrometer
por: Gusev, K E, et al.
Publicado: (2003)

CRMAGE: CRISPR Optimized MAGE Recombineering
por: Ronda, Carlotta, et al.
Publicado: (2016)

MAGE-A Antigens and Cancer Immunotherapy
por: Zajac, Paul, et al.
Publicado: (2017)

Enhancing Efficacy of TCR-engineered CD4(+) T Cells Via Coexpression of CD8α
por: Anderson, Victoria E., et al.
Publicado: (2023)

Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells
por: Mou, D-C, et al.
Publicado: (2002)

Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer
por: Chen, Xinfeng, et al.
Publicado: (2017)

Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer
por: Blumenschein, George R, et al.
Publicado: (2022)

Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma
por: Curioni-Fontecedro, A., et al.
Publicado: (2015)

The XBabelPhish MAGE-ML and XML Translator
por: Maier, Don, et al.
Publicado: (2008)

Correction: Frequent MAGE Mutations in Human Melanoma
por: Caballero, Otavia L., et al.
Publicado: (2010)

Expression of MAGE‐1 Gene by Esophageal Carcinomas
por: Toh, Yuji, et al.
Publicado: (1995)

The Story of the Magee Equations: The Ultimate in Applied Immunohistochemistry
por: Bhargava, Rohit, et al.
Publicado: (2023)

Erratum to “Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma”
por: Curioni-Fontecedro, A., et al.
Publicado: (2019)

The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer
por: Bhargava, Rohit, et al.
Publicado: (2020)

Expression of MAGE-C1/CT7 and MAGE-C2/CT10 Predicts Lymph Node Metastasis in Melanoma Patients
por: Curioni-Fontecedro, Alessandra, et al.
Publicado: (2011)

Expression of melanoma antigen-encoding genes (MAGE) by common primers for MAGE-A1 to -A6 in colorectal carcinomas among Koreans.
por: Park, Myeng-Sun, et al.
Publicado: (2002)

Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases
por: Melo, Daniel Hardy, et al.
Publicado: (2017)

Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer
por: Mohsenzadegan, Monireh, et al.
Publicado: (2022)

NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma
por: Rapoport, Aaron P., et al.
Publicado: (2015)

Demethylation of MAGE promoters during gastric cancer progression
por: Honda, T, et al.
Publicado: (2004)

Genome-scale promoter engineering by Co-Selection MAGE
por: Wang, Harris H., et al.
Publicado: (2012)

MAGE genes: Prognostic indicators in AL amyloidosis patients
por: Liu, Yang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bpbv6md1dp6d2jf7oncf73dsbn